Mammalian target of rapamycin as a target in hematological malignancies

被引：15
|
作者：
Kelly, Kevin R. [1 ]
Rowe, Julie H. [1 ]
Padmanabhan, Swaminathan [1 ]
Nawrocki, Steffan T. [1 ]
Carew, Jennifer S. [1 ]
机构：
[1] Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
来源：
TARGETED ONCOLOGY | 2011年 / 6卷 / 01期
关键词：
mTOR; Hematological malignancies; Novel agents; Targeted therapy; ACUTE MYELOID-LEUKEMIA; MANTLE CELL LYMPHOMA; SINGLE-AGENT TEMSIROLIMUS; PHASE-II TRIAL; EVERY; WEEKS; MULTIPLE-MYELOMA; IN-VIVO; INHIBITOR EVEROLIMUS; PHOSPHOINOSITIDE; 3-KINASE; DEFOROLIMUS AP23573;
D O I：
10.1007/s11523-011-0175-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The mammalian target of rapamycin (mTOR) regulates protein synthesis in addition to cell growth and cell proliferation. Elucidation of the roles of the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway in the regulation of the pathogenesis of hematological neoplasms has led to the development and clinical evaluation of agents targeting this pathway for the treatment of leukemia and lymphomas. Clinical trials conducted to date have shown modest responses to mTOR inhibition in patients with various hematological malignancies. Novel agents that simultaneously target mTOR complex 2 (mTORC2) or AKT in addition to mTOR complex 1 (mTORC1) may offer an opportunity to improve therapeutic efficacy.
引用
收藏
页码：53 / 61
页数：9
相关论文
共 50 条
  • [1] Mammalian target of rapamycin as a target in hematological malignancies
    Kevin R. Kelly
    Julie H. Rowe
    Swaminathan Padmanabhan
    Steffan T. Nawrocki
    Jennifer S. Carew
    Targeted Oncology, 2011, 6
  • [2] Mammalian Target of Rapamycin as a target in hematological malignancies
    Abdel-Karim, Isam A.
    Giles, Francis J.
    CURRENT PROBLEMS IN CANCER, 2008, 32 (04) : 161 - 177
  • [3] Mammalian Target of Rapamycin as a target in hematological malignancies - Foreword
    Kummar, Shivaani
    CURRENT PROBLEMS IN CANCER, 2008, 32 (04) : 160 - 160
  • [4] Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies
    Khokhar, Nushmia Z.
    Altman, Jessica K.
    Platanias, Leonidas C.
    CURRENT OPINION IN ONCOLOGY, 2011, 23 (06) : 578 - 586
  • [5] Exploiting the mammalian target of rapamycin pathway in hematologic malignancies
    Altman, Jessica K.
    Platanias, Leonidas C.
    CURRENT OPINION IN HEMATOLOGY, 2008, 15 (02) : 88 - 94
  • [6] Mammalian target of rapamycin inhibition as therapy for hematologic malignancies
    Panwalkar, A
    Verstovsek, S
    Giles, FJ
    CANCER, 2004, 100 (04) : 657 - 666
  • [7] Mammalian target of rapamycin
    Meric-Bernstam, F
    Mills, GB
    SEMINARS IN ONCOLOGY, 2004, 31 (06) : 10 - 17
  • [8] Mammalian target of rapamycin as a therapeutic target in oncology
    Abraham, Robert T.
    Eng, Christina H.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2008, 12 (02) : 209 - 222
  • [9] Mammalian target of rapamycin as a therapeutic target in osteoporosis
    Shen, Gengyang
    Ren, Hui
    Qiu, Ting
    Zhang, Zhida
    Zhao, Wenhua
    Yu, Xiang
    Huang, Jinjing
    Tang, Jingjing
    Liang, De
    Yao, Zhensong
    Yang, Zhidong
    Jiang, Xiaobing
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (05) : 3929 - 3944
  • [10] Mammalian target of rapamycin as a therapeutic target in leukemia
    Giles, FJ
    Albitar, M
    CURRENT MOLECULAR MEDICINE, 2005, 5 (07) : 653 - 661
12345